Simeprevir and daclatasvir for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1b and advanced liver disease
Year: 2017
Type: article
Study design: Clinical Trial
Source: Liver International
DOI: 10.1111/liv.13376
Institutions: Université Paris-Est Créteil, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, University of Palermo, Ziekenhuisnetwerk Antwerpen Stuivenberg, Asklepios Klinik St. Georg, Institute for Interdisciplinary Medicine, Imperial College Healthcare NHS Trust, St Mary's Hospital, Hospital Clínico Universitario de Valencia, UCLouvain, KU Leuven, Hôpital Saint-Antoine, Semmelweis University, University of Campania "Luigi Vanvitelli", Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Universitari Germans Trias i Pujol, Janssen (Belgium), Goethe University Frankfurt
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Janssen Pharmaceuticals
OpenAlex ID: W2580337443